Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 3(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00732654Phase 1Completed

The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy

Role: collaborator

NCT01353079Phase 3Completed

Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy

Role: lead

NCT00599872Phase 3Completed

Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies

Role: lead

NCT00411606Completed

Normal Values of Facial Thermography

Role: collaborator

All 4 trials loaded